QR Pharma receives FDA clearance to conduct clinical trials with its second novel Alzheimer compound, Bisnorcymserine

QR Pharma Awarded SBIR Grant by NIA/NIH to Test Posiphen® and Metabolites in Various Models

QR Pharma’s Posiphen® was shown in a Clinical Mechanism of Action Study to Enter the Brain and to Inhibit Amyloid Precursor Protein

QR Pharma to Present Positive Results of Posiphen® in a Clinical Mechanism of Action Study at the International Congress on Alzheimer’s Disease 2010

Massachusetts General Hospital and QR Pharma Start a Collaboration on Posiphen® and Parkinson’s Disease

QR Pharma Funding

QR Pharma to Present on Alzheimer’s Disease at the NeuroScienceNetwork

QR Pharma Receives US Patent 7,625,942 to Treat Down Syndrome

QR Pharma Initiates Clinical Trial for Cognitively Impaired Patients

Paul Blake, Hal Broderson and Franz Hefti Join QR Pharma Board Company Taps Region’s Proven Experts in Growing Successful Companies